Vaccine News and Research

Latest Vaccine News and Research

DATATRAK third quarter revenue increases 13% to $2.1 million

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced its operating results for the third quarter of 2011.

10 Nov 2011

POPG inhibits influenza infections in cell cultures and mouse models

A natural lipid in the fluid lining the lungs inhibits influenza infections in both cell cultures and mouse models, according to researchers at National Jewish Health. These findings, combined with previous studies demonstrating effectiveness against respiratory syncytial virus, suggest that the molecule, known as POPG, may have broad antiviral activity.

10 Nov 2011

Large-scale trials show HPV vaccine effective against multiple strains, could reduce need for screening

"Using GlaxoSmithKline's Cervarix vaccine to protect girls against the human papillomavirus (HPV) that causes cervical cancer is so effective that health authorities could reduce the need for later cervical screening," according to two studies published Wednesday in the journal Lancet Oncology, Reuters reports.

9 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011

Interim data from Cytheris CYT107 Phase I/IIa combination study on HCV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.

9 Nov 2011

AMRI reports $50.2 million total revenue for third quarter 2011

...

9 Nov 2011

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Bristol-Myers Squibb Company today announced interim results from a Phase IIb clinical trial (COMMAND-1) of 395 treatment-naïve, genotype 1 and 4 hepatitis C infected patients in which two doses of the investigational NS5A replication complex inhibitor daclatasvir (BMS-790052), in combination with peginterferon alfa and ribavirin (alfa/RBV), achieved higher virologic response rates through Week 12 than the alfa/RBV control group, with comparable rates of adverse events.

9 Nov 2011

Powerful monitoring tool to track spread of seasonal flu

A powerful monitoring tool that will allow researchers to track the spread of seasonal flu launches today. This year the UK Flusurvey will, for the first time, join a European network of online surveys, gathering information on how the illness spreads across the continent and enabling comparison between the different countries.

9 Nov 2011

Bioject third quarter revenues increase to $3.1 million

Bioject Medical Technologies Inc., a leading developer of needle-free drug delivery systems, today reported financial results for the third quarter ended September 30, 2011.

8 Nov 2011

UC Santa Barbara's ImmuNet project focuses on targeted immunizations for infants, children

The University of California, Santa Barbara announced today that it will receive funding through Grand Challenges Explorations, an initiative created by the Bill & Melinda Gates Foundation that enables researchers worldwide to test unorthodox ideas that address persistent health and development challenges. Professors Elizabeth Belding and Amr El Abbadi in the Computer Science Department will pursue an innovative global health research project, titled "ImmuNet: Targeted Immunizations for Infants and Children".

8 Nov 2011

New breast and ovarian cancer vaccine in the pipeline: Study

A new vaccine is being tried clinically to combat tumor cells in a small study of advanced breast and ovarian cancer patients. The results show that there is improvement in overall survival times and stopping the disease for a handful of breast cancer patients.

8 Nov 2011

Forbes cover story profiles Bill Gates, Foundation's work in global health

The November 21 cover story of Forbes magazine profiles Bill Gates, Microsoft founder and co-chair of the Bill & Melinda Gates Foundation, which has focused its global health efforts on vaccine development and distribution, according to the article.

8 Nov 2011

Private sector companies should contribute to GAVI Matching Fund

The GAVI Alliance has "announced a major new initiative aimed at engaging private sector leaders: the GAVI Matching Fund," through which "the British Government's Department for International Development (DFID) and the Bill & Melinda Gates Foundation will provide a 100 percent match of contributions to GAVI from corporations and foundations as well as their customers, members and employees," Bill Roedy, former CEO of MTV Networks and a GAVI Alliance envoy, writes in a post on the Huffington Post's "Impact" blog.

8 Nov 2011

St. Michael's project to develop vaccine that would eliminate latent HIV reservoirs

Dr. Mario Ostrowski, an infectious disease consultant, will pursue an innovative global health research project, titled A Human Endogenous Retrovirus Vaccine to Eliminate Latent HIV Reservoirs.

8 Nov 2011

Live virus used in polio vaccine can evolve and infect, warns TAU researcher

Health professionals and researchers across the globe believe they are on the verge of eradicating polio, a devastating virus which can lead to paralysis and death. Despite successful eradication in most countries, there are still four countries where the virus is considered endemic -- and many more in which the virus still lurks.

8 Nov 2011

Georgia Tech/CDC project focuses on microneedle patches for polio vaccination

Mark Prausnitz, Regents' professor in Georgia Tech's School of Chemical and Biomolecular Engineering, will pursue an innovative global health research project focused on using microneedle patches for the low-cost administration of polio vaccine through the skin in collaboration with researchers Steve Oberste and Mark Pallansch of the US Centers for Disease Control and Prevention.

8 Nov 2011

MBL-HCV1 can reduce viral load in liver transplant patients

A human monoclonal antibody developed by MassBiologics of the University of Massachusetts Medical School (UMMS) given to patients with chronic hepatitis C virus (HCV) infection undergoing liver transplantation significantly suppressed the virus for at least a week after transplant and delayed the time to viral rebound.

8 Nov 2011

Beware mail order Chicken pox warn Doctors

Doctors have warned against a new trend that has emerged via social networking websites like Facebook - one that guides parents through a process of exposing their children to chicken pox, so that they can get the virus, early and avoid any need for vaccination.

7 Nov 2011

Prostate cancer drug market forecast to grow from $3.6 billion in 2010 to $10.1 billion in 2020

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by the launches of several promising emerging therapies, the prostate cancer drug market will experience robust growth over the next decade, increasing from $3.6 billion in 2010 to $10.1 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

7 Nov 2011

Encouraging results from SEEK's FLU-v Phase II study

SEEK, a leading UK privately-owned drug-discovery group, today announced encouraging results following the successful completion of its Universal Flu Vaccine Phase II challenge study.

7 Nov 2011